Clinical trial
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK 001) on the Progression of Stargardt Disease (STGD)
NCT07419334 is registered in ClinicalTrials.gov with Alkeus Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK 001) on the Progression of Stargardt Disease (STGD)
- Lead sponsor
- Alkeus Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- June 3, 2026
- Completion date
- December 31, 2030
- Enrollment
- 230 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.